Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17309854 | 0.87 | SLC6A9 (0.47) | SLC6A9KCNH2GAAALDH1A1 | |
| SCHEMBL19111884 | 0.84 | TRPV4 (0.43) | TRPV4MGLLMET | |
| SCHEMBL13143728 | 0.82 | TRPV4 (0.42) | TRPV4ALDH1A1MGLL | |
| SCHEMBL7634010 | 0.81 | TRPV4 (0.56) | TRPV4SLC6A9ALDH1A1MGLL | |
| SCHEMBL2527854 | 0.79 | TRPV4 (0.40) | TRPV4KCNH2MGLL | |
| SCHEMBL2344031 | 0.79 | XDH (0.53) | — | |
| SCHEMBL12455378 | 0.79 | MRGPRX4 (0.48) | SLC6A9KCNH2GAAALDH1A1 | |
| SCHEMBL31019133 | 0.79 | XDH (0.53) | — | |
| SCHEMBL24225596 | 0.78 | ALDH1A1 (0.44) | GAAALDH1A1 | |
| SCHEMBL2636175 | 0.77 | ALDH1A1 (0.42) | SLC6A9KCNH2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-10807953-B2 | Processes and intermediates for the preparation of Pimavanserin | PLIVA HRVATSKA D.O.O. (HR) | 2020-10-20 | — | — | US | disclosed |
| US-20190276401-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | PLIVA HRVATSKA D.O.O. (HR) | 2019-09-12 | — | — | US | disclosed |
| US-10343993-B2 | Processes and intermediates for the preparation of Pimavanserin | PLIVA HRVATSKA D.O.O. (HR) | 2019-07-09 | — | — | US | disclosed |
| WO-2018098206-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098206-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| US-20180037549-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | TAPI CROATIA INDUSTRIES LTD (HR) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807953-B2 | Processes and intermediates for the preparation of Pimavanserin | PIM1, PIM3, PIM2 | TRPV4 4368/4885SLC6A9 695/4885KCNH2 1769/4885 |
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | TRPV4 4781/4885SLC6A9 3719/4885KCNH2 4512/4885 |
| US-10343993-B2 | Processes and intermediates for the preparation of Pimavanserin | PIM1, PIM3, PIM2 | TRPV4 4368/4885SLC6A9 695/4885KCNH2 1769/4885 |
| US-20190276401-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | PIM1, PIM3, PIM2 | TRPV4 4368/4885SLC6A9 695/4885KCNH2 1769/4885 |
| US-20180037549-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | PIM1, PIM3, PIM2 | TRPV4 4368/4885SLC6A9 695/4885KCNH2 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.